CD274 and non-small cell lung carcinoma: The objective of this study was to assess the comparative effectiveness of two FDA-approved treatment regimens, pembrolizumab + chemotherapy vs nivolumab + ipilimumab, for first-line treatment in patients with NSCLC with PD-L1 TPS ≥1% by employing a MAIC.